Case management deadlines, including expert disclosures and discovery, are being established
Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, et al
Tetrahydrocannabivarin-9 is an antagonist at the CB1 and CB2 receptors and may also act as a glucagon-like peptide-1 (GLP-1) secretagogue
Through this engagement, we are able to perform additional research and generate new genetic insights that are made available to our members
The potential neuroprotective effects of GLP-1RAs by inhibiting neuroinflammation, reducing neuronal apoptosis, and ultimately improving cognitive function in various diseases are beyond doubt
Other trends related to the growth of GLP-1 medicines may cut the other way for food businesses